Fujifilm Diosynth breaks ground on biologics facility

By The Science Advisory Board staff writers

August 19, 2020 -- Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization for biologics, viral vaccines, and gene therapies, held a virtual groundbreaking ceremony on August 19 for its Advanced Therapies Innovation Center construction project in Texas.

The $55 million, 60,000-sq-ft facility is being constructed in College Station and will house dedicated process development and innovation laboratories. The labs will have biosafety level 2 capabilities with advanced upstream, downstream, and analytical development technologies. The building is part of a 22-acre parcel acquired by Fujifilm in June 2020.

The facility will triple the company's advanced therapies and process development capabilities and help the company provide end-to-end gene therapy solutions from preclinical to commercial launch. It is expected to be operational in the fall of 2021.

Copyright © 2020 scienceboard.net
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here